TY - DATA T1 - Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study PY - 2017/11/21 AU - Hidetoshi Kawaguchi AU - Norikazu Masuda AU - Takahiro Nakayama AU - Kenjiro Aogi AU - Keisei Anan AU - Yoshinori Ito AU - Shoichiro Ohtani AU - Nobuaki Sato AU - Shigehira Saji AU - Toshimi Takano AU - Eriko Tokunaga AU - Seigo Nakamura AU - Yoshie Hasegawa AU - Masaya Hattori AU - Tomomi Fujisawa AU - Satoshi Morita AU - Miki Yamaguchi AU - Hiroko Yamashita AU - Toshinari Yamashita AU - Yutaka Yamamoto AU - Daisuke Yotsumoto AU - Masakazu Toi AU - Shinji Ohno UR - https://tandf.figshare.com/articles/journal_contribution/Factors_associated_with_prolonged_time_to_treatment_failure_with_fulvestrant_500_mg_in_patients_with_postmenopausal_estrogen_receptor-positive_advanced_breast_cancer_a_subgroup_analysis_of_the_JBCRG-C06_Safari_study/5563162 DO - 10.6084/m9.figshare.5563162 L4 - https://ndownloader.figshare.com/files/9661231 KW - Breast cancer KW - anti-neoplastic agents KW - post-menopause KW - hormones KW - female KW - treatment failure N2 - Objective: The JBCRG-C06 Safari study showed that earlier fulvestrant 500 mg (F500) use, a longer time from diagnosis to F500 use, and no prior palliative chemotherapy were associated with significantly longer time to treatment failure (TTF) among Japanese patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC). The objective of this sub-group analysis was to further examine data from the Safari study, focusing on ER + and human epidermal growth factor receptor-negative (HER2−) cases. Methods: The Safari study (UMIN000015168) was a retrospective, multi-center cohort study, conducted in 1,072 patients in Japan taking F500 for ER + ABC. The sub-analysis included only patients administered F500 as second-line or later therapy (n = 960). Of these, 828 patients were HER2−. Results Multivariate analysis showed that advanced age (≥65 years; p = .035), longer time (≥3 years) from ABC diagnosis to F500 use (p < .001), no prior chemotherapy (p < .001), and F500 treatment line (p < .001) were correlated with prolonged TTF (median = 5.39 months). Conclusions: In ER+/HER2− patients receiving F500 as a second-line or later therapy, treatment line, advanced age, no prior palliative chemotherapy use, and a longer period from ABC diagnosis to F500 use were associated with longer TTF. ER -